Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Pongtavornpinyo, Wirichada ^a   Yeung, Shunmay ^a,b,d   Hastings, Ian M ^c   Dondorp, Arjen M ^a,d   Day, Nicholas P J ^a,d   White, Nicholas J ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; ARTEMISININ; MEFLOQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; LACTONE;

ARTICLE; HEALTH CARE POLICY; INCIDENCE; MALARIA; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PREVALENCE; SURVIVAL; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION; ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; HUMAN; PARASITOLOGY; PLASMODIUM; THAILAND; THEORETICAL MODEL;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; LACTONES; MALARIA; MODELS, THEORETICAL; PLASMODIUM; THAILAND;

EID: 56649088257     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-229     Document Type: Article

References (46)

1. World Health Organization, Guidelines for the treatment of malaria Geneva 2006 http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
2. Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. N Kumar H Zheng, Parasitol Res 1990 76 214 218 10.1007/BF00930817 2179946
3. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. S Pukrittayakamee K Chotivanich A Chantra R Clemens S Looareesuwan NJ White, Antimicrob Agents Chemother 2004 48 1329 1334 15047537 10.1128/AAC.48.4.1329-1334.2004
4. Effects of artemisinin derivatives on malaria transmissibility. RN Price F Nosten C Luxemburger FO ter Kuile L Paiphun T Chongsuphajaisiddhi NJ White, Lancet 1996 347 1654 1658 10.1016/S0140-6736(96)91488-9 8642959
5. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. KI Barnes NJ White, Acta Trop 2005 94 230 240 15878154
6. Delaying antimalarial drug resistance with combination chemotherapy. NJ White, Parassitologia 1999 41 301 308 10697872
7. Institute of Medicine, Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance Washington, D.C.: The National Academies Press 2004
8. Combination therapy for malaria in Africa: hype or hope? PB Bloland M Ettling S Meek, Bull World Health Organ 2000 78 1378 1388 11196485
9. The de novo selection of drug-resistant malaria parasites. NJ White W Pongtavornpinyo, Proc R Soc Lond B Biol Sci 2003 270 545 554 10.1098/rspb.2002.2241
10. A model for the origins and spread of drug-resistant malaria. IM Hastings, Parasitology 1997 115 Pt 2 133 141 10.1017/S0031182097001261 10190169
11. A malaria model tested in the African savannah. K Dietz L Molineaux A Thomas, Bull World Health Organ 1974 50 347 357 4613512
12. Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. GM Jeffery DE Eyles, Am J Trop Med Hyg 1955 4 781 789 13259002
13. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. NJ White, Antimicrob Agents Chemother 1997 41 1413 1422 9210658
14. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. JK Baird, Ann Trop Med Parasitol 1998 92 367 390 10.1080/00034989859366 9683890
15. Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. JC Beier CN Oster FK Onyango JD Bales JA Sherwood PV Perkins DK Chumo DV Koech RE Whitmire CR Roberts, Am J Trop Med Hyg 1994 50 529 536 7911282
16. Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. C Beadle PD McElroy CN Oster JC Beier AJ Oloo FK Onyango DK Chumo JD Bales JA Sherwood SL Hoffman, J Infect Dis 1995 172 1047 1054 7561179
17. Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. C Rogier D Commenges JF Trape, Am J Trop Med Hyg 1996 54 613 619 8686780
18. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. RW Snow JA Omumbo B Lowe CS Molyneux JO Obiero A Palmer MW Weber M Pinder B Nahlen C Obonyo C Newbold S Gupta K Marsh, Lancet 1997 349 1650 1654 10.1016/S0140-6736(97)02038-2 9186382
19. Environmental and entomological risk factors for the development of clinical malaria among children on the Kenyan coast. RW Snow N Peshu D Forster G Bomu E Mitsanze E Ngumbao R Chisengwa JR Schellenberg RJ Hayes CI Newbold K Marsh, Trans R Soc Trop Med Hyg 1998 92 381 385 10.1016/S0035-9203(98)91056-2 9850385
20. Malaria attacks in children exposed to high transmission: who is protected? C Rogier JF Trape, Trans R Soc Trop Med Hyg 1993 87 245 246 10.1016/0035-9203(93)90110-C 8236379
21. The epidemiology of severe malaria in an area of low transmission in Thailand. C Luxemburger F Ricci F Nosten D Raimond S Bathet NJ White, Trans R Soc Trop Med Hyg 1997 91 256 262 10.1016/S0035-9203(97)90066-3 9231189
22. Contribution of humoral immunity to the therapeutic response in falciparum malaria. M Mayxay K Chotivanich S Pukrittayakamee P Newton S Looareesuwan NJ White, Am J Trop Med Hyg 2001 65 918 923 11791999
23. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. FO ter Kuile F Nosten M Thieren C Luxemburger MD Edstein T Chongsuphajaisiddhi L Phaipun HK Webster NJ White, J Infect Dis 1992 166 1393 1400 1431257
24. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. AL Fontanet AM Walker, Am J Trop Med Hyg 1993 49 465 472 8214276
25. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. G Dorsey MR Kamya G Ndeezi JN Babirye CR Phares JE Olson ET Katabira PJ Rosenthal, Am J Trop Med Hyg 2000 62 686 92 11304055
26. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. SG Staedke H Sendagire S Lamola MR Kamya G Dorsey PJ Rosenthal, Trop Med Int Health 2004 9 624 9 10.1111/j.1365-3156.2004.01239.x 15117308
27. Estimation of incidence and recovery rates of Plasmodium falciparum parasitaemia from longitudinal data. A Bekessy L Molineaux J Storey, Bull World Health Organ 1976 54 685 693 800968
28. Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium. GM Jeffery, Bull World Health Organ 1966 35 873 882 5298036
29. Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. C Rogier AB Ly A Tall B Cisse JF Trape, Am J Trop Med Hyg 1999 60 410 420 10466970
30. Mathematicall modelling of antimalarial drug resistance. W Pongtavornpinyo, PhD Thesis Liverpool School of Tropical Medicine 2006
31. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. WM Watkins CH Sibley IM Hastings, Am J Trop Med Hyg 2005 72 163 173 15741553
32. Tolerance is the key to understanding antimalarial drug resistance. IM Hastings WM Watkins, Trends Parasitol 2006 22 71 77 10.1016/j.pt.2005.12.011 16406706
33. The origins of antimalarial drug resistance. IM Hastings, Trends Parasitol 2004 20 512 518 10.1016/j.pt.2004.08.006 15471702
34. How do patients use antimalarial drugs? A review of the evidence. S Yeung NJ White, Trop Med Int Health 2005 10 121 38 10.1111/j.1365-3156.2004.01364.x 15679555
35. G MacDonald, The epidemiology and control of malaria Oxford: Oxford University Press 1957
36. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. AP Cross B Singer, Trans R Soc Trop Med Hyg 1991 85 349 355 10.1016/0035-9203(91)90286-8 1683034
37. The evolution of drug-resistant malaria: the role of drug elimination half-life. IM Hastings WM Watkins NJ White, Philos Trans R Soc Lond B Biol Sci 2002 357 505 519 12028788 10.1098/rstb.2001.1036
38. Benefits of using multiple first-line therapies against malaria. MF Boni DL Smith R Laxminarayan, Proc Natl Acad Sci USA 2008 105 14216 14221 10.1073/pnas.0804628105 18780786
39. Mating patterns in malaria parasite populations of Papua New Guinea. RE Paul MJ Packer M Walmsley M Lagog LC Ranford-Cartwright R Paru KP Day, Science 1995 269 1709 11 10.1126/science.7569897 7569897
40. Clinically immune hosts as a refuge for drug-sensitive malaria parasites. EY Klein DL Smith MF Boni R Laxminarayan, Malar J 2008 7 67 18439283 10.1186/1475-2875-7-67
41. Epidemiological models for the spread of anti-malarial resistance. JC Koella R Antia, Malar J 2003 2 3 12643812 10.1186/1475-2875-2-3
42. Effect of Artemether-Lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. KI Barnes DN Durrheim F Little A Jackson U Mehta E Allen SS Dlamini J Tsoka B Bredenkamp DJ Mthembu NJ White BL Sharp, PLoS Med 2005 2 e330 16187798 10.1371/journal.pmed.0020330
43. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. A Bhattarai AS Ali SP Kachur A Martensson AK Abbas R Khatib AW Al Mafazy M Ramsan G Rotllant JF Gerstenmaier F Molteni S Abdulla SM Montgomery A Kaneko A Bjorkman, PLoS Med 2007 4 e309 17988171 10.1371/journal.pmed.0040309
44. Exploring 30 years of malaria case data in KwaZulu-Natal, South Africa: part II. The impact of non-climatic factors. MH Craig I Kleinschmidt D le Sueur BL Sharp, Trop Med Int Health 2004 9 1258 66 10.1111/j.1365-3156.2004.01341.x 15598257
45. Spatio-temporal distribution of Plasmodium falciparum and Plasmodium vivax malaria in Thailand. G Zhou J Sirichaisinthop J Sattabongkot J Jones ON Bjornstad G Yan L Cui, Am J Trop Med Hyg 2005 72 256 62 15772317
46. Making antimalarial agents available in Africa. KJ Arrow H Gelband DT Jamison, N Engl J Med 2005 353 333 5 10.1056/NEJMp058168 16000348